Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

Syngene Internation.

₹743 -4.8 | 0.6%

Market Cap ₹29868 Cr.

Stock P/E 59.7

P/B 7.5

Current Price ₹743

Book Value ₹ 99.6

Face Value 10

52W High ₹860.2

Dividend Yield 0.17%

52W Low ₹ 563.6

Syngene Internation. Research see more...

Overview Inc. Year: 1993Industry: Business Support

Syngene International Ltd is a contract research enterprise. The Company is engaged in providing agreement research and manufacturing services in early-stage drug discovery and development to pharmaceutical and biotechnology companies. Its offerings consist of discovery chemistry and biology offerings, toxicology, pharmaceutical development, technique improvement/manufacture of intermediates, active pharmaceutical ingredients and bio-therapeutics. Its services consists of integrated, discovery and development offerings for novel molecular entities (NMEs) across commercial sectors, such as pharmaceutical, biopharmaceutical and biotechnology, amongst others. It specializes in undertaking discovery (from hit to candidate selection), development (together with pre-scientific and clinical studies, analytical and bio-analytical evaluation, and stability studies) and manufacturing (scale-up, pre-clinical and manufacturing components). It serves customers ranging from multinational agencies to start-ups.

Read More..

Syngene Internation. Share Price

New

| |

Volume
Price

Quarterly Price

Show Value Show %

Syngene Internation. Quarterly Results

#(Fig in Cr.) Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 610 641 758 645 768 786 994 808 910 854
Other Income 23 33 24 16 15 17 23 24 22 29
Total Income 634 674 782 660 784 803 1017 832 932 883
Total Expenditure 443 458 517 472 552 555 680 596 656 622
Operating Profit 190 216 265 188 232 248 337 236 276 261
Interest 1 9 6 9 12 14 10 11 13 11
Depreciation 76 79 80 86 90 95 96 102 105 108
Exceptional Income / Expenses -31 0 0 0 0 0 0 0 -7 -4
Profit Before Tax 82 128 179 93 130 140 231 123 151 138
Provision for Tax 16 24 31 19 28 30 52 30 34 27
Profit After Tax 67 104 148 74 102 110 179 93 117 112
Adjustments 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 67 104 148 74 102 110 179 93 117 112
Adjusted Earnings Per Share 1.7 2.6 3.7 1.8 2.5 2.7 4.5 2.3 2.9 2.8

Syngene Internation. Profit & Loss

#(Fig in Cr.) Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 1423 1826 2012 2184 2604 3193 3566
Other Income 136 76 96 83 108 73 98
Total Income 1559 1902 2108 2268 2713 3266 3664
Total Expenditure 1033 1290 1409 1531 1864 2260 2554
Operating Profit 527 612 700 736 849 1005 1110
Interest 23 32 35 28 24 45 45
Depreciation 131 164 219 275 310 367 411
Exceptional Income / Expenses 0 0 71 35 -31 0 -11
Profit Before Tax 373 415 517 469 484 594 643
Provision for Tax 67 84 105 64 89 129 143
Profit After Tax 305 332 412 405 396 464 501
Adjustments 0 0 0 0 0 0 0
Profit After Adjustments 305 332 412 405 396 464 501
Adjusted Earnings Per Share 7.6 8.3 10.3 10.1 9.9 11.6 12.5

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 23% 17% 18% 0%
Operating Profit CAGR 18% 13% 14% 0%
PAT CAGR 17% 4% 9% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 28% 10% 20% NA%
ROE Average 14% 15% 16% 17%
ROCE Average 15% 15% 16% 16%

Syngene Internation. Balance Sheet

#(Fig in Cr.) Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 1720 1968 2176 2821 3298 3618
Minority's Interest 0 0 0 0 0 0
Borrowings 586 347 0 512 532 489
Other Non-Current Liabilities 27 168 325 327 440 466
Total Current Liabilities 784 1129 1539 1133 1229 1188
Total Liabilities 3117 3612 4040 4794 5498 5761
Fixed Assets 1030 1337 1984 2163 2354 2619
Other Non-Current Assets 366 511 444 824 938 717
Total Current Assets 1720 1764 1613 1807 2206 2425
Total Assets 3117 3612 4040 4794 5498 5761

Syngene Internation. Cash Flow

#(Fig in Cr.) Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 235 253 165 193 323 262
Cash Flow from Operating Activities 446 630 677 701 581 824
Cash Flow from Investing Activities -349 -647 -428 -628 -612 -656
Cash Flow from Financing Activities -79 -72 -226 58 -31 -343
Net Cash Inflow / Outflow 18 -89 23 131 -62 -175
Closing Cash & Cash Equivalent 253 165 193 323 262 90

Syngene Internation. Ratios

# Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 7.64 8.29 10.3 10.12 9.88 11.57
CEPS(Rs) 10.92 12.4 15.79 16.99 17.6 20.7
DPS(Rs) 1 0.5 0 0 1 1.25
Book NAV/Share(Rs) 42.31 48.51 53.42 68.61 80.09 88.51
Core EBITDA Margin(%) 27.44 29.34 29.99 29.9 28.43 29.21
EBIT Margin(%) 27.77 24.52 27.41 22.75 19.53 20.01
Pre Tax Margin(%) 26.18 22.75 25.69 21.48 18.6 18.59
PAT Margin (%) 21.46 18.16 20.48 18.54 15.2 14.54
Cash Profit Margin (%) 30.69 27.16 31.38 31.1 27.09 26.02
ROA(%) 9.8 9.86 10.77 9.17 7.69 8.25
ROE(%) 18.05 18.26 20.21 16.59 13.29 13.73
ROCE(%) 15.76 16.98 19.6 15.4 13.24 15.43
Receivable days 68.43 60.53 66.84 73.02 68.92 59.27
Inventory Days 22.06 12.94 6.22 7.09 16.75 29.28
Payable days -5502.04 2997.21 0 -3357.42 -4008.24 -2132.64
PER(x) 38.56 35.46 23.45 53.68 60.44 51.39
Price/Book(x) 6.96 6.06 4.52 7.92 7.45 6.72
Dividend Yield(%) 0.17 0.09 0 0 0.17 0.21
EV/Net Sales(x) 8.15 6.64 5 10.01 9.29 7.49
EV/Core EBITDA(x) 22.02 19.81 14.39 29.69 28.5 23.78
Net Sales Growth(%) 0 28.28 10.2 8.57 19.22 22.61
EBIT Growth(%) 0 13.28 23.19 -9.9 2.33 25.62
PAT Growth(%) 0 8.58 24.28 -1.75 -2.25 17.33
EPS Growth(%) 0 8.58 24.28 -1.75 -2.44 17.16
Debt/Equity(x) 0.47 0.41 0.32 0.28 0.25 0.16
Current Ratio(x) 2.2 1.56 1.05 1.59 1.8 2.04
Quick Ratio(x) 2.13 1.54 1.03 1.55 1.65 1.76
Interest Cover(x) 17.41 13.86 15.94 17.94 21.1 14.13
Total Debt/Mcap(x) 0.07 0.07 0.07 0.04 0.03 0.02

Syngene Internation. Shareholding Pattern

# Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Promoter 70.42 70.41 70.41 70.29 64.86 64.86 54.88 54.8 54.79 54.79
FII 14.07 13.82 13.67 14.12 16.77 16.85 23.28 23.19 23.55 21.2
DII 4.82 4.43 4.43 4.21 6.77 7.04 10.73 11.19 11.7 14.62
Public 10.68 11.33 11.49 11.38 11.6 11.25 11.1 10.82 9.95 9.38
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Debtor days have increased from -4008.24 to -2132.64days.
  • Stock is trading at 7.5 times its book value.
  • The company has delivered a poor profit growth of 8% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Syngene Internation. News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....